Dana-Farber Cancer Institute shared a post on X:
“’If we can identify neoantigens specific to a patient’s tumor, we can make a personalized vaccine to target those tumor-specific antigens,’ says David Braun, MD, PhD, a Dana-Farber oncologist leading a trial of a neoantigen-based vaccine for kidney cancer.”
